Appia Bio today announced that it will present preclinical data on API-192, a first-in-class CAR-NKT allogeneic cell therapy for the treatment of a broad array of B-cell mediated malignancies including non-Hodgkin lymphoma, one of the most common cancers in the U.S.
|
API-192 is a first-in-class off-the-shelf allogeneic CAR-NKT cell therapy that expresses dual CARs targeting CD19 and CD20 and armored with soluble IL-15 for improved expansion and persistence API-192 is the first development candidate out of 2021 collaboration and license agreement with Kite, a Gilead Company LOS ANGELES, Dec. 5, 2023 /PRNewswire/ -- Appia Bio, Inc., a biotechnology company developing allogeneic chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell therapies from hematopoietic stem cells (HSCs) for patients with cancer, today announced that it will present preclinical data on API-192, a first-in-class CAR-NKT allogeneic cell therapy for the treatment of a broad array of B-cell mediated malignancies including non-Hodgkin lymphoma, one of the most common cancers in the U.S.
These data will be delivered in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego, CA. Title: API-192, an Allogeneic CD19/20 CAR-NKT Product Derived from Cord Blood CD34+ HSPCs for the Treatment of B-cell Malignancies API-192 is the first development candidate out of a 2021 collaboration and license agreement between Appia Bio and Kite, a Gilead Company. Under the terms of the agreement, Appia Bio is responsible for preclinical and early clinical research of HSC-derived CAR-NKT product candidates engineered with CARs provided by Kite. Kite is responsible for the later development, manufacturing, and commercialization of the product candidates identified through the collaboration. API-192 is currently undergoing investigational new drug (IND)-enabling studies. "It has been a fantastic team effort to bring API-192 forward as our first development candidate out of our ACUA technology platform. Our research has benefited from the collaboration and support of our partner, Kite-Gilead, and the opportunity to benchmark to the gold standard set by their autologous cell therapy leadership," said JJ Kang, Ph.D., co-founder and chief executive officer of Appia Bio. "We are excited to share these data that support API-192 as a healthy donor derived next-generation allogeneic cell therapy in lymphoma and bring it to patients in the clinic." About API-192 About Appia Bio
SOURCE Appia Bio |
View original content to download multimedia:
